Deutsche Bank Ag\ Bolt Biotherapeutics, Inc. Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.41 - $2.91 $34,435 - $71,068	-24,422 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.74 - $4.82 $28,824 - $50,706	10,520 Added 75.67%	24,422 $67,000
Q4 2021 Feb 11, 2022	SELL	$4.19 - $13.97 $22,877 - $76,276	-5,460 Reduced 28.2%	13,902 $68,000
Q3 2021 Nov 04, 2021	BUY	$11.15 - $18.6 $139,096 - $232,035	12,475 Added 181.14%	19,362 $244,000
Q2 2021 Aug 11, 2021	SELL	$15.4 - $31.46 $23,377 - $47,756	-1,518 Reduced 18.06%	6,887 $106,000

Q1 2021 May 13, 2021	BUY	$25.86 - $39.93 $217,353 - $335,611	8,405 New	8,405 $276,000

24.3M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $28.2M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.